Dec 14, 2010 09:00 DARA BioSciences KRN5500 Reduces Allodynia in Patients With Neuropathic Pain
DARA BioSciences, Inc. (Nasdaq:DARA) announced today additional positive results from its successfully completed KRN5500 Phase 2a Clinical Study for treatment of neuropathic pain in patients with cancer. Statistically significant primary endpoint results were released earlier. continued...
--------------------------------------------------------------------------------
Dec 14, 2010 08:55 SS&C Expands Office Presence in New York City
SS&C Technologies (Nasdaq:SSNC), a global provider of financial services software and software-enabled services, today announced they have signed a 10-year renewal and expansion with The Durst Organization at 675 Third Avenue in New York. continued...